Development of transferrin-bearing vesicles encapsulating aspirin for cancer therapy

Sakpakdeejaroen, Intouch and Somani, Sukrut and Mullin, Margaret and Dufès, Christine (2019) Development of transferrin-bearing vesicles encapsulating aspirin for cancer therapy. Journal of Liposome Research. ISSN 0898-2104 (In Press)

[img] Text (Sakpakdeejaroen-etal-JLR-2019-Development-of-transferrin-bearing-vesicles-encapsulating-aspirin-for-cancer-therapy)
Sakpakdeejaroen_etal_JLR_2019_Development_of_transferrin_bearing_vesicles_encapsulating_aspirin_for_cancer_therapy.pdf
Accepted Author Manuscript
Restricted to Repository staff only until 22 April 2020.

Download (578kB) | Request a copy from the Strathclyde author

    Abstract

    Originally developed for the treatment of inflammatory disorders, the non-steroidal antiinflammatory drug aspirin was shown to have a preventive effect against cancer in the past decades. Most importantly, recent studies suggested that it might also provide a therapeutic benefit in the treatment of cancer in vitro. However, this drug failed to specifically reach tumors at a therapeutic concentration following intravenous administration, thus resulting in lack of efficacy on tumors. In this work, we demonstrated that aspirin could be formulated in transferrin-bearing vesicles and that this tumor-targeted formulation could lead to an increase in the anti-proliferative efficacy of the drug in three cancer cell lines in vitro. The in vitro therapeutic efficacy of aspirin was significantly improved when formulated in transferrin-bearing vesicles, by about 2-fold compared to that of drug solution. These results are promising and support the optimization of this delivery system to further improve its potential as a therapeutic tool in combination with other anti-cancer therapies.